L-Nutra Secures $36.5M to Revolutionize Longevity Through Nutrition Science

L-Nutra, a Los Angeles-based nutrition technology firm, has secured an extra $36.5 million in its latest funding round. The investment pushes the company's Series D total to $83.5 million, with Mubadala leading the effort. Specialising in longevity and medical nutrition, the company claims to be nearing breakthroughs in human healthspan improvement.

The new funding follows L-Nutra's completion of two fresh clinical trials since 2024. These studies focused on its fasting-mimicking diet, exploring benefits for cancer patients and metabolic health. To date, the company has carried out 47 trials and holds 137 patents related to chronic disease remission and longevity.

Joseph Antoun, the firm's chairman and CEO, stated that L-Nutra now stands 'on the cusp of enhancing human healthspan.' The company's work centres on nutrition-based therapies designed to extend healthy lifespans and manage long-term illnesses.

Part of the investment will support a planned joint operation with Mubadala in Abu Dhabi. This facility aims to produce medical nutrition and longevity-focused products for markets across the Middle East and North Africa.

The latest funding boosts L-Nutra's capacity to expand its research and production. With clinical trials ongoing and a new regional hub in development, the company is set to scale its nutrition-based therapies. The partnership with Mubadala also signals growing interest in medical nutrition solutions for global health challenges.